TransMedics Group (NASDAQ:TMDX) Trading Down 4.3% – Time to Sell?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price traded down 4.3% during trading on Thursday . The stock traded as low as $58.90 and last traded at $59.29. 310,211 shares traded hands during trading, a decline of 91% from the average session volume of 3,289,978 shares. The stock had previously closed at $61.97.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of analyst reports. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Robert W. Baird cut their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Piper Sandler lowered their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Finally, TD Cowen cut their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Down 2.8 %

The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of 64.70 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm’s fifty day simple moving average is $69.04 and its 200 day simple moving average is $115.58.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company’s revenue was up 63.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.12) earnings per share. On average, sell-side analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Driehaus Capital Management LLC boosted its holdings in shares of TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after buying an additional 202,867 shares during the last quarter. Geode Capital Management LLC lifted its stake in TransMedics Group by 1.3% in the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after acquiring an additional 10,106 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of TransMedics Group by 5.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after acquiring an additional 30,092 shares during the period. Vaughan Nelson Investment Management L.P. increased its stake in shares of TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of TransMedics Group by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after purchasing an additional 6,634 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.